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Disruption of Dynein/Dynactin Inhibits
Axonal Transport in Motor Neurons Causing
Late-Onset Progressive Degeneration
lien, 2001). ALS is a late onset disease that is character-
ized by progressive muscle weakness that leads to pa-
ralysis and eventual death. Currently, there is no known
cure or effective treatment for this devastating disease,
which has an incidence of roughly 5 in 200,000 people.
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Approximately 5%–10% of ALS cases are familial1Department of Physiology
(FALS), and of these, 15%–20% have a missense muta-School of Medicine and
tion in the gene for Cu/Zn superoxide dismutase I (RosenDepartment of Animal Biology
et al., 1993). Mutations in the heavy subunit of neurofila-University of Pennsylvania
ments (Julien, 1997) and the GTPase alsin (Yang et al.,3700 Hamilton Walk
2001) have also been linked to rare cases of ALS, but2 Department of Pathobiology
the genetic defect or defects responsible for the majoritySchool of Veterinary Medicine
of FALS have not yet been identified. The possibleUniversity of Pennsylvania
causes of sporadic ALS, which is clinically indistinguish-300 Spruce Street
able from FALS, are unknown, but environmental factorsPhiladelphia, Pennsylvania 19104
have been implicated. The wide variety of factors, both3 Wyeth Research
known and unknown, that cause the similar and specific865 Ridge Road
degeneration of motor neurons has made it difficult toPrinceton, New Jersey 08543
understand the pathogenesis of this disease.
One hallmark of motor neuron degeneration observed
in both affected ALS patients and transgenic mice ex-Summary
pressing the SOD-1 mutation is the accumulation of
neurofilaments (NFs) in the perikarya and axons of motorTo test the hypothesis that inhibition of axonal transport
neurons (for review, see Julien, 2001). These cells haveis sufficient to cause motor neuron degeneration such
large caliber axons dependent on neurofilament pro-as that observed in amyotrophic lateral sclerosis
teins for the maintenance of their structure (Xu, et al.,(ALS), we engineered a targeted disruption of the dyn-
1996, Elder et al., 1998a, 1998b). Neurofilaments, likeein-dynactin complex in postnatal motor neurons of
other components of the cytoskeleton, are continuallytransgenic mice. Dynamitin overexpression was found
renewed and require transport from the cell body, whereto disassemble dynactin, a required activator of cyto-
they are synthesized, into and throughout the axon.plasmic dynein, resulting in an inhibition of retrograde
These large filaments are normally transported by micro-axonal transport. Mice overexpressing dynamitin dem-
tubule-based anterograde transport at a rate an orderonstrate a late-onset progressive motor neuron degen-
of magnitude slower than the rate of organelle transport.erative disease characterized by decreased strength
The aberrant accumulation of neurofilament proteinsand endurance, motor neuron degeneration and loss,
has been implicated in the development of motor neuronand denervation of muscle. Previous transgenic mouse
degenerative diseases but may also be an indication ofmodels of ALS have shown abnormalities in microtu-
abnormal transport of these large proteins (Julien, 2001).bule-based axonal transport. In this report, we describe
Several transgenic mouse lines that display a motora mouse model that confirms the critical role of dis-
neuron degenerative phenotype have been shown torupted axonal transport in the pathogenesis of motor
exhibit significant defects in axonal transport. De-neuron degenerative disease.
creased rates of slow axonal transport have been shown
in mice expressing mutant SOD-1 (Collard et al., 1995;
Introduction Zhang et al., 1997; Williamson and Cleveland, 1999). It
has been postulated that defects in axonal transport
Motor neurons of the brain and spinal cord are uniquely may be an underlying common pathway that leads to
characterized by the length of their axons, which can the degeneration of motor neurons in ALS patients and
reach a meter in length in an adult human. The significant transgenic mouse models. In the SOD models, misfold-
length of these cellular projections makes active axonal ing of the mutant SOD-1 protein confers a unique cyto-
transport essential for normal cellular function. This axo- toxic property that may affect the transport machinery
nal transport is microtubule dependent and includes either directly or indirectly. Neurofilament accumulation
both the anterograde transport of organelles to the syn- in transport-deficient axons may then effectively impede
apse and the retrograde transport of multivesicular bod- further transport along microtubules, leading to motor
ies and trophic factors such as NGF back to the cell body. neuron degeneration through “axonal strangulation”
Motor neuron degenerative diseases affect most (Williamson and Cleveland, 1999).
mammals. In humans, amyotrophic lateral sclerosis Cytoplasmic dynein is a molecular motor responsible
(ALS) is a progressive degenerative disorder of motor for minus-end-directed movement along microtubules.
neurons in the cortex, brainstem, and spinal cord (for It is involved in many cellular functions including ER to
reviews, see Borchelt et al., 1998; Cleveland, 1999; Ju- Golgi trafficking and mitotic spindle assembly. In neu-
rons, dynein has an essential role in fast retrograde
axonal transport (Paschal and Vallee, 1987; Hirokawa et4 Correspondence: holzbaur@mail.med.upenn.edu
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al., 1990) as well as in the targeting of developing neu-
rons (Reddy et al., 1997). Dynein has also been proposed
to be a participant in slow anterograde axonal transport
(Dillman et al., 1996), but the mechanism remains elu-
sive. The slow anterograde transport of neurofilaments
may at least in part be dependent on the retrograde
molecular motor dynein and the associated protein com-
plex, dynactin (Shah et al., 2000; Wang et al., 2000).
Dynactin is a multiprotein complex associated with
dynein. Dynactin has been proposed to activate the mo-
tor function of dynein by increasing the processivity and
efficiency of the motor (Waterman-Storer, et al., 1995;
King and Schroer, 2000). Dynactin also participates in
cargo binding (Waterman-Storer et al., 1997; Starr et al.,
1998; Holleran et al., 2001; Muresan et al., 2001). The
largest subunit of dynactin, p150Glued, binds to both mi-
crotubules and the intermediate chain of dynein (Water-
man-Storer et al., 1995; Karki and Holzbaur, 1995). The
base of dynactin consists of the Arp1 filament, which
has been shown to bind to the spectrin matrix found on
organelles and therefore may mediate cargo attachment
(Holleran et al., 1996, 2001; Muresan et al., 2001). Over-
expression of the dynamitin (p50) subunit of dynactin
causes a dissociation of dynactin at the junction of
p150Glued and the Arp1 filament (Echeverri et al., 1996;
Eckley et al., 1999). This effectively renders dynactin
nonfunctional (Echeverri et al., 1996) and has been
shown to inhibit dynein-mediated processes in the cell
(Presley et al., 1997; Burkhardt et al., 1997). Thus, dy-
namitin overexpression is a powerful tool in dissecting
Figure 1. Generation and Characterization of Transgenic Mice Over-the roles of dynein and dynactin in the cell.
expressing DynamitinTo directly test the hypothesis that inhibition in axonal
(A) Construct used to generate dynamitin transgenic mice. An EcoRI-transport may be sufficient to cause motor neuron de-
PvuI fragment of the Thy1.2 expression cassette contains se-generation similar to that observed in ALS, we engineered
quences essential for expression (Caroni, 1997). Human dynamitin
a targeted disruption of the dynein-dynactin complex in cDNA with a FLAG tag was cloned into the XhoI site of the expression
postnatal motor neurons of transgenic mice. Mice over- cassette.
(B) Western blot analysis. Equal amounts of spinal cord total proteinexpressing dynamitin demonstrate a late-onset, slowly
extracts from mice of three founder lines, M5, M13, M21, and wild-progressive motor neuron degenerative disease charac-
type mice were resolved by SDS-PAGE, and a Western blot wasterized by muscle weakness, spontaneous trembling, ab-
done with dynein and the dynactin subunits. The highest dynamitinnormal posture and gaits, and deficits in strength and
expression levels were observed in the M21 line, as expected from
endurance. Dynamitin-overexpressing mice have histo- the RNase protection study.
logical changes in spinal cord motor neurons and skele- (C) Onset of expression in transgenic mice. Brain homogenates from
mouse pups of the M21 line, sacrificed at the indicated time pointstal muscle indicative of degeneration of motor neurons
after birth, were analyzed by SDS-PAGE and Western blot usingand denervation atrophy of muscle. These mice display
antibodies specific for the FLAG tag to determine onset of expres-neurofilament accumulations and a significant inhibition
sion at the protein level. Transgenic expression was observed atof retrograde transport. Previous ALS transgenic mouse
day 13 in M21 mice.
models have shown abnormalities in microtubule based (D) Expression of dynamitin in transgenic mouse tissues. Homoge-
axonal transport. Here we describe a mouse model that nates from brain that had been divided into three equal parts rostral
to caudal on gross dissection and spinal cord samples were ana-confirms the critical role of disrupted axonal transport in
lyzed by SDS-PAGE and Western blot using an affinity-purified anti-the development of motor neuron degenerative diseases.
body to dynamitin. Highest expression levels were seen in the spinal
cord.
Results
Generation and Characterization of Transgenic
Mice Overexpressing Dynamitin (Burkhardt et al., 1997), and axonal outgrowth in cultured
cells (Ahmed et al., 1998). The Thy1.2 expression cas-in Motor Neurons
To examine the functional consequence of disrupting sette was used to drive dynamitin expression because of
its specific high expression in postnatal motor neuronsdynein-mediated axonal transport in the development
of neurodegenerative diseases, we developed three (Caroni, 1997). A FLAG tag was added to the C terminus
of dynamitin to facilitate identification of transgenic ver-lines of transgenic mice that overexpress the dynamitin
subunit of dynactin. Overexpression of this polypeptide sus endogenous dynamitin (Figure 1A). Three founder
mice were identified and bred to establish three sepa-has previously been demonstrated to disrupt dynein
function in cell division (Echeverri et al., 1996), vesicle rate lines of dynamitin-overexpressing transgenic mice.
RNase protection assays on brain tissue were usedtrafficking (Presley et al., 1997), organelle localization
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to quantify the levels of dynamitin overexpression in the expression is in agreement with previous reports that
Thy1.2-driven transgene expression in the mouse is re-transgenic mouse lines (data not shown). Two lines (M5
and M13) had2- to 4-fold increased levels of dynamitin stricted to neurons (Caroni, 1997; Feng et al., 2000).
mRNA. In contrast, the M21 line was estimated to have
an 20-fold increase in dynamitin mRNA levels. Be- Disruption of Dynactin in Motor Neurons
cause of these higher expression levels, we chose to Dynein and dynactin sediment with characteristically
focus on this line for further study. large S values (19S–20S). Overexpression of dynamitin
In order to examine the expression of dynamitin at the results in a shift of dynactin subunits to lower S values
protein level, Western blots of spinal cord homogenates due to the disassembly of the complex into two frac-
from the three transgenic lines as well as age-matched tions; Arp1 and p62 remain in one fraction while p150Glued,
wild-type controls were probed with antibodies to dy- p22, and dynamitin are in another (Echeverri et al., 1996).
namitin (Figure 1B). As expected from the RNase protec- In order to examine the effectiveness of dynamitin over-
tion results, the M21 line was observed to have the expression in disrupting dynactin in the neurons of
highest levels of dynamitin expression. Western blots transgenic mice, high-speed cytosolic extracts of spinal
were also probed with antibodies to other dynactin sub- cord preparations from 5-month-old presymptomatic
units, including p150Glued, p62, Arp1, and p22, to examine mice and wild-type control mice were fractionated by
the relative expression of these polypeptides in the sucrose density gradients (Figure 2). Disruption of the
transgenic lines as compared to wild-type mice (Figure dynactin complex is indicated by the shift of p150Glued,
1B). No significant differences were noted in the expres- dynamitin, and p22 to lower density fractions. Arp1 and
sion of p150Glued, p62, and Arp1 among any of the trans- p62 are shifted by a single fraction, consistent with previ-
genic lines. p22 expression was observed to be more ous observations (Echeverri et al., 1996; Eckley et al.,
variable and may be affected by the expression of the 1999). In wild-type controls, the peak concentration of
transgene. dynactin subunits from wild-type spinal cord extracts
A critical feature of the Thy1.2 expression cassette is remains at 19S–20S. The disruption of dynactin we ob-
that the onset of expression occurs 6–10 days after served in transgenic mouse spinal cord relative to con-
birth (Caroni, 1997). We predicted that this delay in onset trols was extensive, but not complete, most likely due
of expression should allow us to distinguish effects of to the specificity of the Thy1.2 expression cassette for
dynamitin overexpression during embryogenesis from motor neurons. Previous studies with this promoter re-
postnatal effects that may more closely resemble late- veal only limited expression in other neuronal popula-
onset degenerative diseases. This was important be- tions in the spinal cord and none in glial cells (Caroni,
cause dynein and dynactin function are known to be 1997). Further, the immunohistochemistry results de-
required for the normal development of neurons and the scribed below indicate that high levels of dynamitin
assembly of neural circuitry in Drosophila (Murphey et overexpression are not observed in all spinal cord motor
al., 1999; Reddy et al., 1997). In addition, transgenic neurons of M21 mice (see Figure 5).
mice with a null mutation in dynein die in utero (Harada
et al., 1998). Mice Overexpressing Dynamitin Display Evidence
To determine the onset of transgene expression, a of Motor Neuron Degeneration and Skeletal
time course study was performed. M21 pups were sacri- Muscle Atrophy
The onset of disease in transgenic mice from the M21ficed at postnatal days 1, 3, 5, 7, 9, 11, 13, and 21, and
brain homogenates were prepared. Western blots of the line begins between 5 and 9 months of age (Figure 3A).
The severity and progression of the symptoms is vari-homogenates were then probed with antibodies to the
FLAG tag. Expression of the transgene in the M21 line able between littermates, but most M21 mice display
hind end weakness, spontaneous and sometimes spas-was not observed until postnatal day 13 (Figure 1C),
suggesting that abnormalities seen in these transgenic tic tremors, decreased grooming, weight loss, de-
creased fertility, and abnormal gaits. Mice also lose themice are due to the effects of disrupted dynein function
on mature neurons, rather than from disruptive effects ability to extend their hind legs when suspended by the
base of their tail. A less severe phenotype with similarduring motor neuron development. Histological analysis
of the transgenic mice, which revealed no gross pertur- symptoms of hind end weakness, abnormal gaits, and
trembling is observed in the lower expressing M5 andbations or abnormalities in the anatomy or organization
of the nervous system, also supports this conclusion. M13 mouse lines. These milder signs do not develop
until 14–18 months of age.Western blots of all major tissue types from M21 mice
and age-matched controls were examined to analyze Many transgenic mice of the M21 line exhibit abnormal
gaits. Some mice appear to be lame on a limb, or theirthe tissue specificity of transgene expression. Dynactin
is enriched in nervous and muscle tissue; therefore, en- posture is slumped in the hind end. A small number of
transgenic mice become weak in their epaxial musclesdogenous expression of dynamitin is observed in these
tissues (Melloni et al., 1995). In skeletal muscle, there and develop a lordodic posture with an upright tail.
Transgenic mice develop abnormal, slower gaits withis no significant difference in the levels of dynamitin
expression between transgenic and control mice (data decreased stride lengths, which can be demonstrated
by ink tests (see Figure 3C). Mice with signs of weaknessnot shown). Transgenic mice display the highest expres-
sion of dynamitin in neuronal tissues, particularly the also had decreased fertility. Males did not become sick
enough to prevent them from fertilizing females untilspinal cord and hindbrain, as compared to control mice
(Figure 1D). No significant differences in dynamitin ex- they reached the severe stages of the disease. Females,
on the other hand, were not able to successfully raisepression between transgenic and wild-type mice were
observed in any tissue examined other than those from litters once they began to show signs of disease.
Transgenic mice become weak and have difficultythe nervous system (data not shown). This pattern of
Neuron
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Figure 2. Disruption of Dynactin In Vivo by
Overexpressed Dynactin
Homogenates of spinal cord preparations
from 5-month-old wild-type and transgenic
mice were sedimented on 5%–20% sucrose
gradients. Fractions were resolved by SDS-
PAGE, and Western blot was performed using
antibodies specific for the dynactin subunits
p150Glued, p62, dynamitin, Arp1, and p22 as
well as antibodies to the FLAG tag and to
tubulin and actin. Standards were run in par-
allel to determine relative densities of frac-
tions. HSS is pre-load high-speed superna-
tant from mouse spinal cord homogenates. Disruption of the dynactin multiprotein complex is demonstrated by the shift of subunits into
lower density fractions. p150Glued, dynamitin, and p22 divide into a subcomplex that sediments at 4S while Arp1 and p62 shift one fraction
from 4 to 5.
climbing on wire mesh, are not as active in the cage, and presymptomatic transgenic and wild-type male mice,
10- to 14-month-old early symptomatic transgenic anddisplay decreased rearing activity. In order to assess the
weakness that develops in dynamitin-overexpressing wild-type male mice, and17-month-old late symptom-
atic transgenic and wild-type male mice. This protocolmice, analysis of 4- to 7-month-old presymptomatic
transgenic and wild-type male mice, 10- to 14-month- was designed to test the endurance of the animal rather
than the maximum speed that it could run. Early symp-old early symptomatic transgenic and wild-type male
mice, and 17-month-old late symptomatic transgenic tomatic transgenic mice tire on average 44 min earlier
than wild-type mice in the same age group (p  0.02)and wild-type male mice by grip strength meter (Meyer
et al., 1979; Zhao et al., 2001) was performed. Late symp- during treadmill tolerance tests. Late symptomatic
transgenic mice run on average 52 min less than thetomatic transgenic mice exhibit a statistically significant
(p 0.01) decrease in forelimb strength when compared wild-type mice in the same age group (p 0.02), indicat-
ing a decrease in stamina (Figure 3D).to age matched controls (Figure 3E).
Transgenic mice appear to tire easily on the grip
strength meter and when suspended by their tails, so we Motor Neurons in Transgenic Mice Exhibit
Neurofilament Accumulationstested for a decrease in endurance. Treadmill tolerance
tests that tested time to refusal at slow and moderate Four- to seven-month-old presymptomatic transgenic
and wild-type, 10- to 14-month-old early symptomatictreadmill speeds were performed on 4- to 7-month-old
Figure 3. Dynamitin Transgenic Mice Display
a Phenotype Consistent with a Motor Neuron
Degenerative Disease
(A) Late symptomatic, dynamitin-overex-
pressing mouse. Transgenic M21 mice are
weak, especially in the hind end, have abnor-
mal gaits, lose the hind leg extension reflex,
and often spontaneously tremble.
(B) Age-matched negative mouse.
(C) Dynamitin-overexpressing mice have de-
creased stride length and gait abnormalities.
Wild-type versus late symptomatic trans-
genic mice were sent through a one-direc-
tional chute with painted feet to demonstrate
stride abnormalities.
(D) Early and late symptomatic transgenic
mice tire before age-matched negatives on
treadmill endurance tolerance tests. Mice
were exercised on a mouse treadmill at slow
to moderate speeds in order to compare their
stamina. Early and late symptomatic trans-
genic mice tire more than 40 min earlier than
their age-matched wild-type controls. Shown
are mean running times  SE (t test, *p 
0.02).
(E) Early and late symptomatic transgenic
mice demonstrate decreased strength on a
grip strength meter. Forelimb strength was
determined by averaging three trials after
force exerted on the meter was corrected for
mouse weight. Late symptomatic transgenic
mice are significantly weaker than age-
matched controls. Mean kg force/kg
weight  SE (t test, *p  0.001).
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transgenic and wild-type, and 17-month-old late there was intense staining of dynamitin in spinal cord
symptomatic transgenic and wild-type mice spinal cord motor neurons, not every motor neuron was expressing
cross-sections from the lumbar intumescence were dynamitin, consistent with previously observed expres-
stained with hemotoxylin and eosin (H&E). In presymp- sion patterns driven by the Thy1.2 promoter (Feng et
tomatic and early symptomatic transgenic mice not ex- al., 2000).
hibiting clinical signs of disease, no gross anatomical Neurofilament staining was examined to determine if
or significant histological changes were observed in the disruption of the dynactin complex affects neurofila-
brains or spinal cords (data not shown). In the early ment distribution. Overall, neurofilament staining was
stages of the disease, significant degenerative changes more intense in spinal cord sections of early symptom-
would be expected to be seen at the distal end of axons, atic transgenic mice (Figures 5E, 5K, and 5Q) compared
which are most dependent on transport. In presymptom- to age-matched negatives (Figures 5B, 5H, and 5N).
atic and early symptomatic mice, no loss of motor neu- Neuronal processes are swollen with neurofilaments,
rons nor inclusions in cell bodies or processes were and spheroids, similar to those seen with H&E, stain for
observed, and only very minor, subtle histological neurofilaments (Figure 5Q). The neurofilament antibody
changes such as swollen axons were seen in early symp- used recognizes only phosphorylated heavy and light
tomatic mice. Histological changes were evident in17- subunits, so as expected, neurofilament staining was
month-old late symptomatic transgenic mice when com- not observed in the cell bodies of motor neurons. Periph-
pared to wild-type mice in the same age group (Figures eral nerves containing motor neuron fibers from trans-
4A and 4B). Degeneration and moderate loss of motor genic mice also have higher accumulations of neurofila-
neurons are seen in the ventral horns of dynamitin-over- ments as compared to wild-type mice (data not shown).
expressing mice (Figure 4B, inset). Transgenic sections Sections of brain and spinal cord were also stained
have a spongiform appearance with debris in areas of with synaptophysin as a marker for axonal transport.
possible cellular loss (Figure 4B, white arrow). Loss of Synaptophysin is a ubiquitous membrane protein asso-
axons is evident in the long tracks of spinal cord white ciated with small synaptic vesicles and is present in all
matter (Figure 4B, black arrow). The loss of motor neu- synaptic terminals (Navone et al., 1986). In a recent
rons was also confirmed by examining the number of study, dynein and synaptophysin were found to partially
axons seen in L5 ventral roots (see Figure 6). Swollen colocalize and accumulate at both the proximal and
axons are also seen (Figure 4B, white arrowheads), re- distal ends of a nerve injury crush (Li et al., 2000). Consis-
sembling the spheroids described in the spinal cord of tent with a defect in axonal transport, accumulation of
ALS patients. synaptophysin was seen at the periphery of neurons in
Skeletal muscle was examined from whole limbs and the ventral horn of spinal cord sections of early symp-
epaxials from 4- to 7-month-old presymptomatic trans- tomatic transgenic mice (Figures 5F, 5L, and 5R) as
genic and wild-type, 10- to 14-month-old early symp- compared to the distribution of synaptophysin in control
tomatic transgenic and wild-type, and 17-month-old mice (Figures 5C, 5I, and 5O).
late symptomatic transgenic and wild-type mice. As with
other tissues examined, no significant abnormalities are Examination of L5 Ventral Roots
seen in the pre- and early symptomatic mice, but abnor-
by Electron Microscopy
malities are observed in the late symptomatic transgenic
To determine the effects of dynamitin overexpression
mice (Figures 4C and 4D). Widespread evidence of de-
on axonal numbers and caliber, L5 ventral roots of 4-
nervation atrophy and regeneration is seen, but is most
to 7-month-old presymptomatic transgenic and wild-pronounced in the large hind limb flexors such as the
type mice, 10- to 14-month-old early symptomatic andbiceps femoris. Obvious histological changes such as
wild-type mice, and 16-month-old late symptomaticsmall angular fibers (Figure 4D, black arrows) indicating
and wild-type mice were examined by light and electrondenervation, centrally placed nuclei (Figure 4D, arrow-
microscopy. Ventral roots are comprised primarily ofheads), and hypertrophic fibers (Figure 4D, asterisk)
myelinated axons originating from motor neurons andwere observed. Changes in muscle fibers are seen in
are an accurate reflection of their numbers. Four- tosmall groups, suggesting that previous events of dener-
seven-month-old presymptomatic transgenic mice havevation and reinnervation by neighboring motor neurons
100%  5% of the total number of axons observed inhave occurred (Figure 4D, white arrow).
wild-type mice of the same age group. Ten- to fourteen-Initial screening for dynamitin expression and evi-
month-old early symptomatic transgenic mice havedence of disrupted transport in early symptomatic trans-
92%  4% of the total number of axons found in wild-genic mice at the onset of phenotype compared to age-
type mice in the same age group. A decrease of 25% matched controls was done by immunohistochemistry
6% was found in the average total number of axonsusing antibodies to dynamitin, neurofilaments, and syn-
counted in the 16-month-old late symptomatic trans-aptophysin. Ten- to fourteen-month-old early symptom-
genic mice when compared to wild-type mice of theatic transgenic and wild-type mice were examined. Sec-
same age group (t test, p  0.08).tions of fore-, mid-, and hindbrain as well as cervical,
We then counted the number of small caliber (5 mthoracic, and lumbar spinal cord were screened. Sec-
in diameter) axons (SCAs) and large caliber (5 m intions of brain showed limited expression of dynamitin
diameter) axons (LCAs) in 4- to 7-month-old presymp-in transgenic mice and no unusual staining of neurofila-
tomatic, 10- to 14-month-old early symptomatic,ments or synaptophysin (data not shown). Spinal cord
and16-month-old late symptomatic mice to determinemotor neurons in the ventral horn of early symptomatic
if one population of axons was selectively vulnerable totransgenic mice stained intensely for dynamitin (Figures
the effects of transgene expression. 4- to 7-month-old5D, 5J, and 5P), but not in age-matched controls (Figures
5A, 5G, and 5M). It should be noted that even though presymptomatic transgenic mice have no significant dif-
Neuron
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Figure 4. Hemotoxilin and Eosin Staining of Transgenic and Age-Matched Wild-Type Mouse Spinal Cord and Skeletal Muscle Tissue Sections
(A) Ventral horn of spinal cord cross-section from lumbar intumescence of a 14-month-old wild-type mouse. Note the large motor neuron cell
bodies in the ventral horn, which is bordered by white matter.
(B) Ventral horn of spinal cord cross-section from approximately the same region of a 14-month-old symptomatic transgenic mouse. Fewer
motor neuron cell bodies are seen, as quantified by counting axons in the L5 ventral root (see Figure 6). The spongiform appearance of gray
matter with debris also indicates cellular loss (white arrow). Some degenerate motor neurons are seen (see vacuolations of cell body in insert).
Swollen axons or spheroids are observed (white arrowheads), as well as loss of white matter in the long spinal tracts (black arrow).
(C) Cross-section of muscle from the large hind limb flexors (biceps femoris) of the age-matched wild-type mouse in (A).
(D) Cross-section of the same muscle from the symptomatic transgenic mouse in (B). Muscle fiber central nuclei (black arrowhead) and small
angular fibers (black arrow) indicate degeneration and atrophy from denervation. Clusters of muscle fibers undergoing similar changes (white
arrow) demonstrate a conversion from the normal heterogeneous innervation. Compensatory hypertrophy of muscle fibers (asterisk) is also
seen. Scale bar is 20 m.
ferences in the number of the SCAs (98%  3%) and In the 16-month-old late symptomatic transgenic
mice (Figure 6F), evidence of degeneration and axonalLCAs (101%  1%) when compared to wild-type mice
in the same age group. Ten- to fourteen-month-old early loss is seen when compared to wild-type mice of the
same age group (Figure 6E). There are degenerate ax-symptomatic transgenic mice have 96%  4% of the
SCAs and 90%  4% of the LCAs of wild-type mice in ons, axonal inclusions, myelin defects, and an increase
in space between axons, suggesting axonal loss (Figurethe same age group. A significant decrease (t test, p 
0.02) was found in the number of LCAs of 16-month- 6F). These observations are similar to those described
in EM analysis of ventral roots in mutant SOD-1 miceold late symptomatic transgenic mice when compared
to 16-month-old wild-type mice. Late symptomatic (Bruijin et al., 1997). We also observed many axons with
involutions or invaginations of the myelin sheath intotransgenic mice have 99%  2% of SCAs but only
65%  2% of the LCAs found in 16-month-old wild- the axons, indicating axonal atrophy and suggesting a
deficient or collapsed cytoskeleton.type mice.
No abnormalities or significant differences are found
in L5 ventral roots of 4- to 7-month-old presymptomatic Delay in Retrograde Transport Observed in Early
Symptomatic Transgenic Micetransgenic mice (Figure 6B) when compared to wild-
type mice (Figure 6A). In the 10- to 14-month-old early In order to directly correlate the degenerate changes
seen in motor neurons and their axons and the develop-symptomatic transgenic mice (Figure 6D), an upward
trend in the variability of axonal caliber is noted with no ment of the observed phenotype in transgenic mice with
disruptions in axonal transport, neurotracer studiessignificant loss of axonal numbers when compared to
wild-type mice in the same age group as described were performed. Transgenic mice and age-matched
wild-type controls were injected with the retrogradeabove (Figure 6C). This loss of axonal caliber size main-
tenance may be due to deficiencies in the slow transport neurotracer fluoro-gold in the gastrocnemius muscle
and sacrificed at 44 and 46 hr to determine the numberof neurofilaments.
Dynamitin Overexpression Causes Neurodegeneration
721
Figure 5. Immunohistochemistry of Spinal Cord Sections from Transgenic Mice.
Panels in the left column (A, D, G, J, M, and P) are stained for dynamitin, those in the center column (B, E, H, K, N, and Q) for phosphorylated
neurofilaments, and those in the right column (C, F, I, L, O, and R) for synaptophysin. Panels (A), (B), (C), (G), (H), (I), (M), (N), and (O) are age-
matched wild-type mice and panels (D), (E), (F), (J), (K), (L), (P), (Q), and (R) are from M21 transgenic mice. Panels (A)–(F) are 5 (scale bar 
200 m), (G)–(L) are 20 (scale bar  50 m), and (M)–(S) are 100 (scale bar  10 m). Note the elevated and specific levels of dynamitin
expression in motor neurons of the ventral horn in dynamitin-stained panels of transgenic mice (D, L, and P). Large aggregates of neurofilament
in cell processes as well as axonal swellings (black arrows) are seen in (E), (K), and (Q). There is also increased staining for synaptophysin in
transgenic mice (F and L) and accumulation at the cell periphery of motor neurons (black arrows in [R]). Sections from wild-type and transgenic
mice were developed in parallel according to a fixed protocol.
of motor neuron cell bodies that had accumulated flu- Accumulation of the fluoro-gold neurotracer was ob-
served in whole motor neuron pools that innervate theoro-gold (Schmued, 1994). No significant differences
were detected in presymptomatic mice. Retrograde injected muscle at the 44 and 46 hr time points in wild-
type mice and is demonstrated in Figure 7B. In contrast,transport could not be quantitated in late symptomatic
transgenic mice because of the significant loss of motor transgenic mice in the same age group had only an
occasional cell with fluoro-gold accumulation at the 44neurons found in this group. Therefore quantitation of
transport deficits was performed on 10- to 14-month- and 46 hr time points (Figure 7A), while still possessing
normal motor neuron numbers in this age group of miceold early symptomatic transgenic mice in comparison
to wild-type controls. (H&E results and Figure 7A, inset). These rare labeled
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Figure 6. Electron Microscopy of Presymp-
tomatic, Early Symptomatic, and Late Symp-
tomatic Transgenic Mice and Age-Matched
Wild-Type Mice
Representative electron microscopy images
of L5 ventral roots in cross-section. There are
no appreciable differences in appearance or
number of axons in 4- to 7-month-old wild-
type (A) and presymptomatic transgenic mice
(B). 10- to 14-month-old wild-type (C) and age-
matched early symptomatic transgenic mice
(D) have similar numbers of axons, but there is
a trend toward a larger variation in axonal
caliber seen in early symptomatic transgenic
mice. 16-month-old wild-type (E) and late
symptomatic transgenic mice (F) have statis-
tically different numbers of axons and consid-
erable changes in their appearance. Late
symptomatic transgenic mice have a dropout
of 25%  6% in the total number of axons
as compared to wild-type mice in the same
age group (t test, p  0.08). This correlates
with a statistically significant (t test, p  0.02)
decrease in the number of large (5m diam-
eter) caliber axons of 35%  2% when com-
pared wild-type mice in the same age group.
Images from late symptomatic transgenic mice
demonstrate increased space between ax-
ons, supporting axonal loss as well as degen-
erate axons, inclusions, and defects in my-
elination (F). Scale bar is 10 m.
cells may correspond to motor neurons that do not over- Sciatic nerve ligations of symptomatic transgenic
express dynamitin, as high levels of dynamitin were ob- mice and age-matched controls were also performed to
served in only a subset of motor neurons (Figure 5). probe for possible differences in anterograde transport.
At 44 hr, the average number of labeled cells per However, over a 2–6 hr time course, no consistent, ap-
mouse is 46.5  16.5 (average  SE; n  6) in wild-type preciable difference could be found between transgenic
mice, whereas the average number of labeled cells per and wild-type mice. Given the relatively short time frame
mouse is 15.2  8.5 (n  4) in early symptomatic 10- of this experiment and the limited overexpression of
to 14-month-old transgenic mice (p  0.135). At 46 hr dynamitin to motor neurons within a mixed cell popula-
postinjection of fluoro-gold, a significant decrease of tion in the sciatic nerve, definitive conclusions cannot
labeled cells was found in transgenic mice (Figure 7A) be drawn about the possible effects of dynamitin over-
when compared to the accumulation observed in wild- expression on anterograde axonal transport. The signifi-
type mice (Figure 7B). An average of 48.7  7.4 (n  6) cant inhibition of retrograde rather than anterograde
labeled cells per wild-type mouse was found, whereas transport in the transgenic mice is consistent with dyn-
an average of only 16.0  5.8 labeled cells per mouse ein’s role as a minus-end-directed microtubule motor.
was found in early symptomatic transgenic mice (t test,
p  0.01) (Figure 7C). At later time points, preliminary
Discussionobservations have shown that in transgenic mice, the
fluoro-gold neurotracer accumulates in motor neuron
Motor neuron degenerative diseases are severely debili-pools more similarly to wild-type controls (data not
tating and largely fatal in humans as well as other mam-shown), suggesting that dynamitin overexpression de-
malian species. Several hypotheses have been pro-lays but does not completely block retrograde axonal
transport. posed to explain the pathogenesis of these diseases,
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long axons that rely heavily on the transport of organ-
elles and cytoskeletal proteins for the health and mainte-
nance of the cell. In fact, transgenic mouse models of
known FALS mutations, such as the SOD-1 mutant, have
been examined for axonal transport deficiencies. De-
creased transport times of cargo in both slow and fast
anterograde transport have been found weeks before
the onset of clinical symptoms (Cleveland, 1999). The
dynamitin-overexpressing transgenic mouse model we
report here addresses the question of whether a specific
targeted disruption of microtubule-based transport is
sufficient to recapitulate a motor neuron degenerative
disease.
Overexpression of dynamitin has been a powerful tool
in the elucidation of the cellular functions of dynein and
dynactin. Previous experiments performed in vitro or in
transfected tissue culture cells have demonstrated that
elevated dynamitin levels lead to the specific disruption
of the dynactin complex and the interruption of several
dynein-mediated cellular functions, including minus-
end-directed microtubule transport (Echeverri et al.,
1996; Burkhardt et al., 1997; Presley et al., 1997; Eckley
et al., 1999). Here we describe a transgenic mouse over-
expressing dynamitin, leading to significant disruption
of dynactin in the motor neurons of the spinal cord.
We have achieved high levels of motor neuron-specific
dynamitin expression using the Thy1.2 expression cas-
sette, with significant protein levels observed after post-
natal day 13. This postdevelopmental onset of transgene
expression allowed us to focus on the role of transport
in mature neurons, in contrast to previous studies in
Drosophila (Reddy et al., 1997) and mice (Harada et
al., 1998), which demonstrated a key role for dynein/
dynactin in development.
Dynein is a unidirectional motor responsible for retro-
grade vesicle transport along microtubules. While dyn-
ein is not thought to have an active role in anterograde
fast transport, previous studies have shown a link be-
tween plus-end- and minus-end-directed motors. For
example, in extruded squid axoplasm, blocking the in-
teraction of dynein and dynactin was observed to result
in a bidirectional block in vesicle transport along micro-
tubules (Waterman-Storer et al., 1997). A similar bidirec-
Figure 7. Early Symptomatic Mice Have a Decrease in the Number of tional inhibition of motility was induced using anti-
Motor Neurons Labeled by the Retrograde Neuro-Tracer Fluoro-Gold kinesin antibodies (Brady et al., 1990). In Drosophila,
Longitudinal spinal cord section from the lumbar intumescence of genetic interactions between dynein, dynactin, and
a 10- to 14-month-old early symptomatic transgenic mouse injected kinesin have been observed, also resulting in a bidirec-
with the retrograde neuro-tracer fluoro-gold and sacrificed at 46 hr
tional inhibition of axonal transport (Martin et al., 1999).postinjection (A). No accumulation in the cell bodies of motor neuron
Dynein and dynactin have also been proposed to havepools is seen except for a rare singly labeled cell. Counter stain of (A)
a role in slow anterograde transport (Dillman et al., 1996),to visualize motor neuron pool in spinal cord (A, inset). Longitudinal
section of spinal cord from wild-type age-matched mouse sacrificed but their exact function, as well as the mechanism of
at 46 hr postinjection demonstrating accumulation of fluoro-gold in slow transport, remains unknown. Dynein and dynactin
motor neuron pools (B). At 44 hr, an average of 31 more motor have been found to be associated with isolated neurofil-
neurons in wild-type mice accumulate fluoro-gold than transgenic aments and to catalyze the transport of these filaments
mice, and at 46 hr, an average of 33 more motor neurons label in
along microtubules in vitro (Shah et al., 2000). Recentthe wild-type mice than the early symptomatic transgenic mice of
live cell imaging of cultured neurons transfected withthe same age group (t-test, *p  0.01). Scale bar is 50 m.
GFP-labeled neurofilament M subunit has suggested
that the net velocity of neurofilament slow transport is
but none addresses the underlying cause for the speci- actually comprised of fast anterograde transport that is
ficity of disease in motor neurons, the late onset of the interrupted by either pauses or retrograde movements
disease, and the cumulative progressive nature of the (Wang et al., 2000). Net slow transport of these filaments
disease. Deficiencies or interruptions in axonal transport down the axon may result from the dual activity of the
have been previously proposed to lead to degeneration opposing motors kinesin and dynein.
of affected motor neurons. This is not unreasonable, Therefore, it is conceivable that disruption of dynein/
dynactin would essentially eliminate slow transport be-because motor neurons are large cells with extensively
Neuron
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cause of the nonopposition to kinesin, and all antero- rely extensively on microtubule-based transport for their
grade transport would then be at fast rates, including survival. Previous studies on transgenic mouse models
the transport of neurofilaments. This would account for of FALS have found defects in axonal transport, but
the accumulation of neurofilaments observed in axons the question remained whether defective transport is
of affected neurons rather than more proximally or in the sufficient to cause the disease. In this report, we de-
cell body, reflecting a specific defect in dynein/dynactin- scribe a clear connection between the disruption of dyn-
mediated transport. An interesting possibility is that the ein/dynactin by the overexpression of dynamitin, de-
saltatory retrograde movements that Wang et al. (2000) creased retrograde transport times of a neuro-tracer
saw when observing NF transport were performing a cargo, and the degeneration of motor neurons and their
function critical to NF transport rather than merely re- axons with the development of a phenotype consistent
flecting the result of inefficient transport. The long with a motor neuron degenerative disease. In this mouse
pauses and retrograde movements of NFs seen may model, overexpression of dynamitin inhibits but does
result from the necessity to “space out” the transport not completely eliminate retrograde transport. This inhi-
of these large polymers down the axon, thus relieving bition results in cumulative damage to the motor neuron,
steric hindrance to further transport. The upward trend leading to degeneration and eventual cell death. Further
in the variability of axonal caliber seen in early symptom- characterization of the interplay between inhibition of
atic transgenic mice (Figure 7D) may be the result of transport and neuronal degeneration in these mice, as
a loss of caliber maintenance resulting from inhibited well as the potential compensatory sprouting and regen-
retrograde function. The drop out of large caliber axons eration that prolong the disease time course in the dy-
observed in late symptomatic mice would then demon- namitin transgenic mice, should provide additional in-
strate the critical role this loss of maintenance has on sight into the specific roles of dynein and dynactin as
axonal survival. well as provide further understanding of the underlying
Transgenic mice in the M21 line do not develop overt mechanisms for the pathogenesis of motor neuron loss
clinical signs until 5–9 months of age, and the onset of observed in diseases such as ALS.
disease is variable. The rate of decline between lit-
termates is also variable, often with episodes of decline Experimental Procedures
and improvement. Mice typically display initial minor
Generation of Transgenic Micespontaneous fine muscle tremors that progress over
The full-length human cDNA encoding dynamitin was obtained fromtime to more violent, spastic tremors. Hind limb weak-
the ATCC as previously described (Karki et al., 1998). The cDNAness is commonly seen, resulting in decreased rearing
was modified by PCR using the primers p505 (TAGCTCGAGCCATGactivity, difficulty walking, occasional hopping with both
GCGGACCCTAAATACGC) and p503 (TAGCTCGAGTCACTTGTCG
hind limbs, and decreased stride length. Forelimb weak- TCATCGTCTTTGTAGTCCTTTCCCAGCTTCTTCATCCGTTCATCAA
ness is also seen, but less commonly. Although the TGC) to include a C-terminal FLAG tag to facilitate the identification
presentation and onset of clinical signs in these mice of the transgene. The resulting construct was subcloned into the
XhoI site of the Thy1.2 mouse expression cassette (a generous giftare more variable than that seen in the SOD-1 mouse
of P. Caroni), generating pThy1.2p50flag (Figure 1A). The EcoRI-model, they may more closely resemble the clinical pre-
PvuI fragment containing the expression cassette with the p50flagsentation of the spontaneous form of ALS in humans
transgene was isolated from vector sequence and purified by gel
than do previous animal models. electrophoresis, Qiaex purification, and passing over an Elutip ion
One possibility for the observed variability of clinical exchange column (Schleicher & Shuell, Keene, NH). The DNA was
signs associated with the overexpression of dynamitin then ethanol precipitated, resuspended in injection buffer (10 mM
Tris/0.1 mM EDTA [pH 7.5]) at a concentration of 1–5 g/l, andmay be compensation at the cellular level. Overex-
submitted to the Transgenic Facility at the University of Pennsylva-pressed dynamitin could be sequestered in some fash-
nia School of Medicine for injection into fertilized C57BL/6 homozy-ion by the upregulation of another dynactin subunit, p22.
gous mouse eggs.Supporting this theory is the observation that complete
Positive offspring were identified by PCR of tail biopsies using
fragmentation of dynactin results in the partitioning of the 5 primer DH16 (CTTGGACCTCATGCAGTAGG) and the 3 primer
p22 and dynamitin in the same fraction of sucrose gradi- pu2p50 (GGATCTCCAGCCCTCAAG). Fourteen mice were shown to
ents (Eckley et al., 1999). Preliminary data suggest that be positive for the transgene. These mice were then screened for
germline integration of the transgene by backcrossing with B6SJL/levels of p22 expression vary inversely with the severity
F1 mice (Jackson Labs, Bar Harbor, ME), which were chosen forof phenotype observed. Another possibility to explain
hybrid vigor, and three mice (M5, M13, and M21) were identified asthe variation in phenotype seen in these mice could
founders. All of the animals used in these studies were kept in abe the variation of transgene expression seen in motor
pathogen-free environment, and the experimental procedures were
neurons. Although expression is very specific and high approved by the IACUC committee at the University of Pennsylvania.
in motor neurons, not every motor neuron displays high
levels of transgene expression. This variation of Thy1.2 RNase Protection Assays
expression in subsets of motor neurons has been pre- RNase protection assays were performed to quantify the levels of
viously observed (Feng et al., 2000). While denervation dynamitin expression in transgenic mice. RNA was isolated from
of a muscle fiber would result in its degeneration, that mouse brains using the RNAwiz kit (Ambion, Austin, TX) according
to the manufacturer’s instructions. RNA was prepared from age-fiber could recover if it was reinnervated by sprouting
matched negative mice and representatives from the three lines offrom a neighboring healthy motor neuron. Until the num-
founder mice. The DNA probe was prepared from an antisenseber of motor neurons affected begins to compromise
clone of the PCR product using the primers DH16 and pu2p50 from
the innervation of the entire muscle, an overt phenotype pThy1.2p50. The probe was labeled using the RPA II kit from Ambion
will not be displayed. and [-32P]UTP. Approximately 1.5  106 dpm of labeled RNA was
Deficiencies in axonal transport have long been postu- added to each sample and incubated in the hybridization buffer
overnight at 45	C.lated to initiate degeneration of motor neurons, which
Dynamitin Overexpression Causes Neurodegeneration
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RNase of the hybridization mixture was done according to manu- with the treadmill incline set at 20	 until determined to be exhausted
by their refusal to run despite short resting periods (1 min restsfacturer’s directions, and the resulting product resolved on a 5%
polyacrylamide/8 M urea gel. Gels were dried down under vacuum on platform) and gentle prodding with a tongue depressor. Mice
were started at a belt speed of 9 m/min for 20 min and then pro-at 75	C for 60 min onto filter paper (Fisher, Pittsburgh, PA) and
exposed overnight to X-Omat Blue film (Kodak, Rochester, NY) with gressed to 12 m/min up to 2 hr running time, after which mice were
run at 17 m/min until refusal to run. This protocol of slow to moderatedouble intensifying screens at 
80	C. Levels of expression were
determined by analysis of the blot by NIH Image. speeds was designed to test the endurance time of the mouse rather
than the maximum speed that the mouse could run (Pagala et al.,
1998). 4- to 7-month-old presymptomatic (phenotype score 0, n 8),Biochemical Characterization of Dynamitin and Dynactin
10- to 14-month-old early symptomatic (phenotype score  1–2,in Wild-Type and Transgenic Mice
n  5), 17-month-old late symptomatic (phenotype score  3–4,Western analysis of transgenic and wild-type mouse tissues was
n  6), and age-matched wild-type control mice were examined,done to determine the onset and pattern of Thy1.2p50flag expres-
mean running time and SE were calculated, the t test was applied,sion. Brain and spinal cord extracts were prepared by homogeniza-
and p values of 0.02 were determined for mice in the 10- to 14-tion in buffer A (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA)
month-old and 17-month-old age groups.plus protease inhibitors (AEBSF, aprotinin, leupeptin, pepstatin A,
In order to quantify the decrease in strength observed in symp-TAME) (Echeverri et al., 1996) and resolved on 10% SDS-PAGE gels.
tomatic transgenic mice, a grip strength meter was used (ColumbusGels were transferred to Immobilon-P membranes, blocked in 5%
Instruments) as previously described (Meyer et al., 1979, Zhao, etnon-fat dry milk in TBS plus 0.5% Igepal, and probed with the
al., 2001). Briefly, male mice grasp a triangular ring that is connectedmonoclonal antibodies anti-kinesin (Chemicon, Temecula, CA), anti-
to a tension digital force transducer and is gently pulled by the taildynamitin (Transduction Labs, San Diego, CA), and anti-FLAG
away from the bar that measures the maximum tension produced.(Sigma, St Louis, MO). Polyclonal antibodies used were anti-Arp1
Three trials are done consecutively on each mouse with no more(Holleran et al., 1996), anti-p150Glued (Melloni et al., 1995), anti-p22
than 30 s between each trial, and the three values are averaged and(Karki et al., 1998), and anti-p62 (Karki et al., 2000). An anti-dynamitin
corrected for the weight of the mouse to produce a kg of tensionpolyclonal antibody was produced as previously described for
produced per kg weight of the mouse. 4- to 7-month-old presymp-p150Glued (Tokito et al., 1996). Rabbits were immunized using the
tomatic (phenotype score  0, n  41), 10- to 14-month-old earlyrecombinant full-length human dynamitin. Antibodies were affinity
symptomatic (phenotype score  1–2, n  29), 17-month-old latepurified from the serum against the antigen.
symptomatic (phenotype score  3–4, n  7), and age-matchedTissues screened were forebrain, midbrain, cerebellum, brain
wild-type control mice were examined, mean tension/weight andstem, spinal cord, heart, lung, liver, spleen, testes, uterus, ovaries,
SE were calculated, the t test was applied, and a p value of 0.001and forelimb and hind limb muscles from the wild-type and trans-
was determined for mice in the 17-month-old age group.genic mice. Tissues were homogenized in buffer B (20 mM Tris-
HCL [pH 7.4], 2 mM EGTA, 1 mM EDTA) plus protease inhibitors
(leupeptin, pepstatin A, TAME, and PMSF). Homogenates were re- Immunohistochemistry
Histology was performed on early and late symptomatic transgenicsolved by 8% SDS-PAGE as described above, transferred to Immo-
bilon-P membranes, blocked with 5% milk solution, and probed and age-matched negative control mice to further characterize the
pathology produced from dynamitin overexpression in motor neu-with polyclonal anti-dynamitin. Visualization was done with the non-
radioactive Renaissance kit (NEN, Boston, MA) according to the rons. Tissues were fixed overnight in 10% formalin, paraffin embed-
ded, and processed by standard protocols. Tissues screened weremanufacturer’s directions.
High-speed supernatants were made from spinal cord homoge- brain and spinal cord as well as thoracic and lumbar whole limbs.
Sections were cut into 12m sections and stained with H&E (Fisher).nates of 5-month-old presymptomatic transgenic and wild-type
mice in buffer A plus protease inhibitors and fractionated on sucrose Immunohistochemistry was performed on 10- to 14-month-old
early symptomatic transgenic and wild-type mice in parallel. Cross-gradients. Approximately 200 l of homogenates was overlaid onto
a 12 ml, 5%–20% sucrose gradient and centrifuged at 32 K for sections of spinal cord formalin fixed, paraffin embedded slides
were processed by standard protocols to dissolve paraffin, perme-18 hr. Simultaneously, gradients loaded with the markers aldolase,
catalase, BSA, thyroglobulin, and lysozyme were run in parallel as abilized with Proteinase K, and blocked with 0.03% hydrogen perox-
ide. Primary antibodies used were: mouse monoclonal anti-dynami-standards to determine the 20S and 4S fractions. One milliliter frac-
tions were collected from each gradient and resolved by 10% SDS- tin (Chemicon) and rabbit polyclonals anti-neurofilament (M0762)
and anti-synaptophysin (Dako, Carpinteria, CA). The anti-neurofila-PAGE. Gels were transferred to Immobilon-P membranes, blocked
with 5% milk solution, and probed with the monoclonal antibodies ment polyclonal antibody M0762 recognizes the phosphorylated
forms of the light and heavy subunits only. Antibodies were conju-to tubulin, actin, the FLAG tag, and the polyclonal antibodies anti-
Arp1, anti-p150Glued, anti-p22, anti-dynamitin, and anti-p62. gated directly to horseradish peroxidase using the LSAB2 kit from
Dako according to the manufacturer’s directions and visualized with
DAP (Dako). Sections were counterstained with hemotoxylin. Histol-Characterization of Transgenic Phenotype
ogy and immunohistochemistry sections were processed and evalu-Mice were regularly monitored to assess the onset, severity, and
ated by the pathobiology department of the University of Pennsylva-progression of symptoms associated with transgene expression.
nia School of Veterinary Medicine.Mice were examined by a veterinarian to determine the phenotype
and assigned a score of 0 to 5, concurrent with severity. Mice with
a score of 0 did not show any clinical signs while a 5 indicated Electron Microscopy
Pre-, early, and late symptomatic dynamitin transgenic and age-paralysis. Mice were euthanized when they were determined to have
a significant loss of weight, indicating an inability to reach food, or matched control mice were deeply anesthetized with an intraperito-
neal injection of ketamine/xylazine (1 mg/gm and 0.1 mg/gm), sacri-when they became moribund. All transgenic mice used in these
experiments were categorized into presymptomatic, early symp- ficed by intracardiac perfusion, and their L5 ventral roots harvested
and processed for EM analysis as previously described (Zhang ettomatic, or late symptomatic to normalize the extent of clinical signs
of the mice used in the experiments. Presymptomatic mice are al., 1997). Briefly, mice were fixed by perfusion with 30–50 ml of
2% glutaraldehyde and 2% paraformaldehyde in 0.1 M cacodylatedefined as being 4- to 7-month-old and have a phenotype score of
0. Early symptomatic mice are 10- to 14-month-old and have a buffer. The L5 ventral roots were removed, postfixed in 1% osmium
tetroxide for 20 min, and processed for embedding in Epon-Aralditephenotype score of 1–2, whereas late symptomatic mice are 17-
month-old and older and have a phenotype score of 3–4. Stride resin. Ultrathin sections were cut, mounted in 100 mesh or open grids,
and stained with 1% uranyl acetate and 0.5% lead citrate. Grids werelength was analyzed by placing the mice in a one-directional chute
laid with paper following painting of their feet with a nontoxic paint. analyzed with a 100CX Joel Electron Microscope at 80 kV.
Quantitation of L5 ventral roots was performed as in Bruijin et al.Treadmill tolerance tests of mice were done on a 6-lane belt-driven
treadmill constructed for mice from Columbus Instruments (Columbus, (1997). Mice were grouped as follows: 4- to 7-month-old wild-type
(n  2) and presymptomatic transgenic mice (n  2), 10- to 14-OH). After acclimation to the instrument, male mice were exercised
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month-old wild-type (n  2) and early symptomatic mice (n  2), plex disrupts dynein-dependent maintenance of membrane organ-
elle distribution. J. Cell Biol. 139, 469–484.and 16-month-old wild-type (n  3) and late symptomatic trans-
genic mice (n 3). The total number of axons in the ventral roots was Caroni, P. (1997). Overexpression of growth-associated proteins in
determined (t test, p  0.08 for 16-month-old late symptomatic the neurons of adult transgenic mice. J. Neurosci. Methods 71, 3–9.
transgenic mice) and reported as a percentage of the total number Cleveland, D.W. (1999). From Charcot to SOD1: mechanisms of
of axons in age-matched control mice. Large (5 m in diameter) selective motor neuron death in ALS. Neuron 24, 515–520.
and small (5 m in diameter) axons were counted for transgenic
Collard, J.-F., Coˆte, F., and Julien, J.-P. (1995). Defective axonalmice in each age group (t test, p  0.02 for the decrease in LCAs
transport in a transgenic mouse model of amyotrophic lateral sclero-found in the 16-month-old late symptomatic transgenic mice) and
sis. Nature 375, 61–64.reported as a percentage of the number of small or large axons
Dillman, J.F., III, Dabney, L.P., Karki, S., Paschal, B.M., Holzbaur,found in wild-type mice in the same age group.
E.L.F., and Pfister, K.K. (1996). Functional analysis of dynactin and
cytoplasmic dynein in slow axonal transport. J. Neurosci. 16, 6742–Fluoro-Gold Neurotracer Experiments
6752.Ten- to fourteen-month-old early symptomatic and wild-type control
Echeverri, C.J., Paschal, B.M., Vaughan, K.T., and Vallee, R.B. (1996).mice were used for the determination of retrograde transport using
Molecular characterization of the 50-kD subunit of dynactin revealsthe neurotracer fluoro-gold (FluoroChrome, Denver, CO). Mice were
function for the complex in chromosome alignment and spindleimmobilized in a restraint tube (Harvard Apparatus, Holliston, MA),
organization during mitosis. J. Cell Biol. 132, 617–633.and the caudal aspect of the left lower hind limb was clipped and
prepped. A small stab incision was made in the skin 2–3 mm long Eckley, D.M., Gill, S.R., Melkonian, K.A., Bingham, J.B., Goodson,
to expose the underlying muscle at the widest point of the lower H.J., Heuser, J.E., and Schroer, T.A. (1999). Analysis of dynactin
limb (7–10 mm distal to the femorotibial joint). A 10 l Hamilton subcomplexes reveals a novel actin-related protein associated with
syringe was used to deliver 1 l of a 2% solution of fluoro-gold (wt/ the Arp1 minifilament pointed end. J. Cell Biol. 147, 307–319.
vol) in 0.9% saline at a medial, central, and lateral site approximately Elder, G.A., Friedrich, V.L., Kang, C., Bosco, P., Gourov, A., Tu, P.-H.,
2 mm deep in the gastrocnemius muscle of the mouse. Mice were Lee, V.M.-Y., and Lazzarini, R.A. (1998a). Requirement of heavy neu-
sacrificed at 44 and 46 hr by CO2 inhalation, the lumbar intumes- rofilament subunit in the development of axons with large calibers.
cence of the spinal cord was harvested and fixed in 4% paraformal- J. Cell Bio1 143, 195–205.
dehyde made in PBS and floated in 20% sucrose until the cords
Elder, G.A., Friedrich, V.L., Bosco, P., Kang, C., Gourov, A., Tu, P.-H.,sank (usually overnight), and longitudinal sections were prepared
Lee, V.M.-Y., and Lazzarini, R.A. (1998b). Absence of the mid-sizedby standard methods. Sections were visualized using an A2 filter
neurofilament subunit decreases axonal calibers, levels of light neu-on a Leica DMRB epifluorescence microscope, and the total number
rofilament (NF-L), and neurofilament content. J. Cell Biol. 141,of motor neurons accumulating fluoro-gold in their cell bodies was
727–739.counted for each mouse. The mean number of cell bodies accumu-
Feng, G., Mellor, R.H., Bernstein, M., Keller-Peck, C., Nguyen, G.T.,lating fluoro-gold and SE was calculated for wild-type (n 6) versus
Wallace, M., Nerbonne, J.M., Lichtman, J.W., and Sanes, J.R. (2000).early symptomatic transgenic (n  4) 10- to 14-month-old mice for
Imaging neuronal subsets in transgenic mice expressing multiplethe 44 hr and 46 hr time points.
spectral variants of GFP. Neuron 28, 41–51.
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